Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
1 other identifier
observational
60
1 country
1
Brief Summary
Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 10, 2023
CompletedFirst Posted
Study publicly available on registry
September 18, 2023
CompletedStudy Start
First participant enrolled
October 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedSeptember 18, 2023
September 1, 2023
2 months
September 10, 2023
September 15, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Immunohistochemistry
Thin sections will be taken from paraffin embedded tissue samples and placed on barcode glass slides After deparaffinization and rehydration, the sections will be subjected to histopathological evaluation using hematoxylin and eosin staining.We use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval
up to three weeks after pterygium surgery
Study Arms (3)
control group
group 1 -control group normal conjunctiva from 30 patients
group 2 primary pterygia
primary pterygia samples from 30 patients
group 3 recurrent pterygia
recurrent pterygia samples from 30 patients
Interventions
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
Eligibility Criteria
60 patient with primary and recurrent pterygium
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hümeyra Yildirim
Balıkesir, 10100, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
HÜMEYRA YILDIRIM
Balıkesir Medical Faculty
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 4 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Expression of CD44, PCNA and E-cadherin in pterygium tissue
Study Record Dates
First Submitted
September 10, 2023
First Posted
September 18, 2023
Study Start
October 1, 2023
Primary Completion
December 1, 2023
Study Completion
January 1, 2024
Last Updated
September 18, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share